Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
February 26, 2020 07:00 ET
|
Momenta Pharmaceuticals, Inc.
-- Reported favorable interim data from Phase 1/2 study of M254 in ITP, supporting expansion of Part B; expect to report updated data in Q2 2020 and launch additional Phase 2 study in CIDP in Q4 2020...
Momenta Pharmaceuticals to Webcast Presentation at the Cowen 40th Annual Health Care Conference
February 19, 2020 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2019 Financial Results Conference Call and Webcast
February 12, 2020 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Provides Year-End 2019 Update and 2020 Outlook
January 13, 2020 07:10 ET
|
Momenta Pharmaceuticals, Inc.
-- Interim Phase 1 / 2 data of M254 in ITP supports expansion of lower dose cohorts; additional data expected Q2; plan to initiate Phase 2 study in CIDP – -- Nipocalimab (M281) MG study 80% enrolled;...
Momenta Pharmaceuticals Announces CFO Transition
January 03, 2020 08:05 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) (“Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel...
Momenta Pharmaceuticals to Webcast Presentation at the 38th Annual J.P. Morgan Healthcare Conference
December 24, 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 24, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that Craig Wheeler, President and CEO, will present at the 38th Annual J.P. Morgan...
Momenta Pharmaceuticals Appoints Dr. Jane F. Barlow to Board of Directors
December 13, 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced the appointment of Jane F. Barlow, M.D., M.P.H., M.B.A. to its Board of Directors. ...
Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock
December 12, 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced the pricing of its underwritten public offering of 14,516,130 shares of its common...
Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock
December 10, 2019 16:04 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced that it is commencing an underwritten registered public offering of $200,000,000 of...
Momenta Pharmaceuticals Announces Poster Presentation at the 61st American Society of Hematology Annual Meeting and Exposition
November 07, 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that Santiago Arroyo, M.D., Ph.D., Chief Medical Officer, will deliver a poster...